Published in Lancet Infect Dis on October 06, 2011
Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl) (2015) 1.61
Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol (2014) 1.49
Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One (2013) 1.41
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. N Engl J Med (2017) 1.39
New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS (2013) 0.98
Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia. PLoS One (2013) 0.95
Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive patients in Indonesia. J Int AIDS Soc (2014) 0.91
Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. Curr Trop Med Rep (2015) 0.87
Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis. Future Virol (2013) 0.84
Asymptomatic cryptococcemia in resource-limited settings. Curr HIV/AIDS Rep (2013) 0.80
The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS--'25 years of research through partnerships'. Trop Med Int Health (2014) 0.79
Pregnancy in HIV clinical trials in Sub Saharan Africa: failure of consent or contraception? PLoS One (2013) 0.79
Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens. J Int Assoc Provid AIDS Care (2014) 0.78
Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. Philos Trans R Soc Lond B Biol Sci (2016) 0.75
Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda. BMC Infect Dis (2017) 0.75
Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence. Open Forum Infect Dis (2016) 0.75
Preventing AIDS deaths: cryptococcal antigen screening and treatment. Lancet Infect Dis (2012) 0.75
Prevention of AIDS-associated cryptococcosis in resource-poor areas. Lancet Infect Dis (2011) 0.75
Nutritional status and its effect on treatment outcome among HIV infected clients receiving HAART in Ethiopia: a cohort study. AIDS Res Ther (2016) 0.75
The impact of antiretroviral therapy on symptom burden among HIV outpatients with low CD4 count in rural Uganda: nested longitudinal cohort study. BMC Palliat Care (2017) 0.75
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis (2010) 4.08
Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS (2002) 3.99
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health (2007) 3.69
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis (2003) 3.04
A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 2.29
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med (2004) 1.80
The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS (1994) 1.70
Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis (1998) 1.61
Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa. J Acquir Immune Defic Syndr (2011) 1.56
Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS (2006) 1.55
Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) (1993) 1.50
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. Cochrane Database Syst Rev (2008) 1.48
Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet (1995) 1.46
The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. J Infect (2001) 1.43
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis (2006) 1.43
Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 1.32
Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev (2006) 1.17
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis (2007) 1.16
Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One (2010) 1.15
Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev (2005) 1.13
Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment. Trop Med Int Health (2010) 1.07
Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS (1992) 1.04
A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis (2001) 1.02
A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. HIV Med (2001) 0.90
Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. Scand J Infect Dis (1995) 0.83
Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection. AIDS (1995) 0.83
Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis. HIV Med (2005) 0.81
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med (2008) 6.41
Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med (2005) 5.05
Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet (2008) 4.70
Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health (2009) 4.69
Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med (2007) 4.56
Perpetration of partner violence and HIV risk behaviour among young men in the rural Eastern Cape, South Africa. AIDS (2006) 4.45
The costs and effectiveness of four HIV counseling and testing strategies in Uganda. AIDS (2009) 4.45
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 4.33
Risk factors for domestic violence: findings from a South African cross-sectional study. Soc Sci Med (2002) 3.90
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med (2009) 3.85
Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health (2007) 3.69
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med (2016) 3.59
Biological and behavioural impact of an adolescent sexual health intervention in Tanzania: a community-randomized trial. AIDS (2007) 3.51
Transactional sex with casual and main partners among young South African men in the rural Eastern Cape: prevalence, predictors, and associations with gender-based violence. Soc Sci Med (2007) 3.29
Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS (2007) 3.26
Rape of girls in South Africa. Lancet (2002) 3.16
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural population cohort 1989-2005. AIDS (2008) 3.01
Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS (2002) 2.93
Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr (2010) 2.83
Undiagnosed HIV infection and couple HIV discordance among household members of HIV-infected people receiving antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr (2006) 2.73
HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet (2002) 2.64
Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health (2010) 2.62
Incidence of HIV infection in stable sexual partnerships: a retrospective cohort study of 1802 couples in Mwanza Region, Tanzania. J Acquir Immune Defic Syndr (2002) 2.60
Desire for children and pregnancy risk behavior among HIV-infected men and women in Uganda. AIDS Behav (2006) 2.59
Distribution of hyperglycaemia and related cardiovascular disease risk factors in low-income countries: a cross-sectional population-based survey in rural Uganda. Int J Epidemiol (2010) 2.52
Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS (2005) 2.50
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis (2011) 2.32
Time for fair trade in research data. Lancet (2009) 2.29
Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis (2008) 2.26
Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer (2006) 2.25
Making HIV prevention programmes work. Lancet (2008) 2.22
Investigation and treatment of imported malaria in non-endemic countries. BMJ (2013) 2.21
Snake envenoming: a disease of poverty. PLoS Negl Trop Dis (2009) 2.20
Wound healing with honey--a randomised controlled trial. S Afr Med J (2006) 2.16
Effect of home-based water chlorination and safe storage on diarrhea among persons with human immunodeficiency virus in Uganda. Am J Trop Med Hyg (2005) 2.12
Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 2.10
Use of antenatal services and delivery care in Entebbe, Uganda: a community survey. BMC Pregnancy Childbirth (2007) 2.08
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med (2005) 2.06
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Depression and CD4 cell count among persons with HIV infection in Uganda. AIDS Behav (2006) 2.01
Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res (2008) 1.97
Evaluation of six commercial point-of-care tests for diagnosis of acute dengue infections: the need for combining NS1 antigen and IgM/IgG antibody detection to achieve acceptable levels of accuracy. Clin Vaccine Immunol (2011) 1.97
Reach and cost-effectiveness of the PrePex device for safe male circumcision in Uganda. PLoS One (2013) 1.91
Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study. J Infect Dis (2005) 1.88
Oral cholera vaccines: use in clinical practice. Lancet Infect Dis (2006) 1.85
Preparedness of Tanzanian health facilities for outpatient primary care of hypertension and diabetes: a cross-sectional survey. Lancet Glob Health (2014) 1.81
Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr (2012) 1.79
Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm. Bull World Health Organ (2009) 1.76
HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda. Sex Transm Infect (2011) 1.75
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med (2011) 1.68
A community-based study to examine the effect of a youth HIV prevention intervention on young people aged 15-24 in South Africa: results of the baseline survey. Trop Med Int Health (2005) 1.65
Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials?: A modeling study. J Acquir Immune Defic Syndr (2004) 1.65
Asking semi-literate adolescents about sexual behaviour: the validity of assisted self-completion questionnaire (ASCQ) data in rural Tanzania. Trop Med Int Health (2004) 1.65
HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res Hum Retroviruses (2011) 1.63
Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes. AIDS (2003) 1.63
High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sex Transm Dis (2012) 1.62
Risk factors for HIV infection in injection drug users and evidence for onward transmission of HIV to their sexual partners in Chennai, India. J Acquir Immune Defic Syndr (2005) 1.61
A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings. Open AIDS J (2007) 1.60
Integrating research into routine service delivery in an antiretroviral treatment programme: lessons learnt from a cluster randomized trial comparing strategies of HIV care in Jinja, Uganda. Trop Med Int Health (2008) 1.58
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis (2002) 1.56
Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS Med (2011) 1.53
Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection. Clin Vaccine Immunol (2012) 1.52
Home-based antiretroviral care is associated with positive social outcomes in a prospective cohort in Uganda. J Acquir Immune Defic Syndr (2007) 1.52
The role of vertical transmission and health care-related factors in HIV infection of children: a community study in rural Uganda. J Acquir Immune Defic Syndr (2007) 1.52
Beyond Testing: Empirical Models of Insurance Markets. Annu Rev Econom (2010) 1.50
The impact of age on the epidemiology of incomplete abortions in South Africa after legislative change. BJOG (2005) 1.49
The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. Int J Epidemiol (2013) 1.48
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods (2009) 1.46
HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. Sex Transm Dis (2011) 1.45
Anaemia in a rural Ugandan HIV cohort: prevalence at enrolment, incidence, diagnosis and associated factors. Trop Med Int Health (2008) 1.44
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med (2012) 1.44
Suboptimal patterns of provider initiated HIV testing and counselling, antiretroviral therapy eligibility assessment and referral in primary health clinic attendees in Blantyre, Malawi. Trop Med Int Health (2012) 1.41
HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda. AIDS (2007) 1.41
Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda. Trop Med Int Health (2009) 1.39
The MEMA kwa Vijana project: design of a community randomised trial of an innovative adolescent sexual health intervention in rural Tanzania. Contemp Clin Trials (2005) 1.39
A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis (2010) 1.39